乙酰唑胺治疗慢阻肺或肥胖低通气综合征呼吸衰竭合并代谢性碱中毒的系统评价
该系统评价纳入4项随机对照试验共504例患者(99%为慢阻肺),比较乙酰唑胺与安慰剂对慢性呼吸疾病急性加重合并代谢性碱中毒的疗效。结果显示乙酰唑胺对死亡率(RR 0.98,95%CI 0.28-3.46)和通气支持时长(MD -0.8天,95%CI -7.2至5.6)均无显著差异,证据质量低。结论认为乙酰唑胺可能影响甚微,但不能排除临床显著获益或危害,需更大规模试验。
要点
- 乙酰唑胺对慢阻肺合并代谢性碱中毒患者的死亡率无显著影响(RR 0.98,95%CI 0.28-3.46)。
- 乙酰唑胺对通气支持时长无显著缩短(MD -0.8天,95%CI -7.2至5.6)。
- 现有证据质量低,不能排除临床显著获益或危害,需更大规模试验验证。
核心结论
- 乙酰唑胺可能对慢性呼吸疾病患者因代谢性碱中毒导致的呼吸衰竭影响甚微。
- 但不能排除临床显著的获益或危害,需要更大规模的试验来确认。
研究设计与样本
- 系统评价与荟萃分析,检索Medline、EMBASE和CENTRAL从建库至2022年3月。
- 纳入比较乙酰唑胺与安慰剂的随机对照试验,对象为慢阻肺、肥胖低通气综合征或阻塞性睡眠呼吸暂停住院患者,伴急性呼吸恶化合并代谢性碱中毒。
- 共纳入4项研究,504例患者;99%为慢阻肺,无阻塞性睡眠呼吸暂停试验,50%试验招募了需要机械通气的患者。
- 主要结局为死亡率,采用随机效应荟萃分析合并数据;使用Cochrane RoB 2评估偏倚风险,I2值和χ2检验评估异质性,GRADE评估证据确定性。
主要发现
- 乙酰唑胺组与安慰剂组死亡率无统计学显著差异(相对风险0.98,95%CI 0.28至3.46;p=0.95;490例参与者;3项研究;GRADE低确定性)。
- 乙酰唑胺组与安慰剂组通气支持时长无统计学显著差异(平均差-0.8天,95%CI -7.2至5.6;p=0.36;427例参与者;2项研究;GRADE低确定性)。
- 纳入试验的偏倚风险总体为低至有一定风险。
关键数值与推荐
- 死亡率:相对风险0.98(95%CI 0.28至3.46),p=0.95,基于490例参与者、3项研究,GRADE低确定性。
- 通气支持时长:平均差-0.8天(95%CI -7.2至5.6),p=0.36,基于427例参与者、2项研究,GRADE低确定性。
临床怎么用
- 对于慢阻肺或肥胖低通气综合征患者因代谢性碱中毒导致的呼吸衰竭,乙酰唑胺的常规使用缺乏高质量证据支持。
- 临床决策需个体化,充分考虑现有证据的低确定性,不能排除获益或危害。
局限性
- 纳入研究数量少(4项),样本量有限(504例),且99%患者为慢阻肺,外推性受限。
- 无阻塞性睡眠呼吸暂停患者的试验数据,该人群证据缺失。
- 主要结局和通气支持时长的证据确定性均为低(GRADE低确定性)。
- 仅50%试验招募了需要机械通气的患者,可能影响对重症患者的推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic alkalosis may lead to respiratory inhibition and increased need for ventilatory support or prolongation of weaning from ventilation for patients with chronic respiratory disease. Acetazolamide can reduce alkalaemia and may reduce respiratory depression. METHODS: We searched Medline, EMBASE and CENTRAL from inception to March 2022 for randomised controlled trials comparing acetazolamide to placebo in patients with chronic obstructive pulmonary disease, obesity hypoventilation syndrome or obstructive sleep apnoea, hospitalised with acute respiratory deterioration complicated by metabolic alkalosis. The primary outcome was mortality and we pooled data using random-effects meta-analysis. Risk of bias was assessed using the Cochrane RoB 2 (Risk of Bias 2) tool, heterogeneity was assessed using the I2 value and χ2 test for heterogeneity. Certainty of evidence was assessed using GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) methodology. RESULTS: Four studies with 504 patients were included. 99% of included patients had chronic obstructive pulmonary disease. No trials recruited patients with obstructive sleep apnoea. 50% of trials recruited patients requiring mechanical ventilation. Risk of bias was overall low to some risk. There was no statistically significant difference with acetazolamide in mortality (relative risk 0.98 (95% CI 0.28 to 3.46); p=0.95; 490 participants; three studies; GRADE low certainty) or duration of ventilatory support (mean difference -0.8 days (95% CI -7.2 to 5.6); p=0.36; 427 participants; two studies; GRADE: low certainty). CONCLUSION: Acetazolamide may have little impact on respiratory failure with metabolic alkalosis in patients with chronic respiratory diseases. However, clinically significant benefits or harms are unable to be excluded, and larger trials are required. PROSPERO REGISTRATION NUMBER: CRD42021278757.
引用
- Bemand TJ, Chatoor R, Natale P, et al. Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review. Thorax. 2023. PMID: 37217290. doi:10.1136/thorax-2023-219988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。